sdü tıp fak derg

Medical Journal of Süleyman Demirel University

2602-2109

Süleyman Demirel Üniversitesi

10.17343/sdutfd.1066328

Surgery

Cerrahi

PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) FOR A COMPLEMENTARY TARGET THERAPY IN GLIAL TUMORS

GLİAL TÜMÖR TEDAVİSİNDE TAMAMLAYICI HEDEF TEDAVİ: PROSTAT SPESİFİK MEMBRAN ANTİJEN (PSMA)

https://orcid.org/0000-0002-1735-4062

Oğuzoğlu

Ali Serdar

SÜLEYMAN DEMİREL ÜNİVERSİTESİ

https://orcid.org/0000-0002-1714-3150

Şenol

Nilgün

SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ

https://orcid.org/0000-0002-5470-6784

Yasan

Hasan

SÜLEYMAN DEMİREL ÜNİVERSİTESİ

https://orcid.org/0000-0002-9418-8862

Yüceer

Ramazan Oğuz

SÜLEYMAN DEMİREL ÜNİVERSİTESİ

https://orcid.org/0000-0002-8222-3384

Gazeloğlu

Cengiz

SÜLEYMAN DEMİREL ÜNİVERSİTESİ

https://orcid.org/0000-0002-5619-4989

Çiriş

İbrahim Metin

SÜLEYMAN DEMİREL ÜNİVERSİTESİ

03 01 2022

29 1 133 137 02 01 2022 02 07 2022

1994

Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

ObjectiveGliomas are the most common primary brain tumorswith different grades. Especially in the high grade gliomastumor angiogenesis is an essential component,and a valuable marker for the prognosis. In this stuıdywe aimed to evaluate the expression of prostate specificmembrane antigen (PSMA) in glial tumors by immunochemistry method to determine different targetedtherapies.Material and MethodsOverall 93 patients’ specimens, including Grade II(n=22), Grade III (n=19), Grade IV (n=52) glial tumors,were evaluated for PSMA-antibody via immunohistochemicalmethod. PSMA staining intensities in tumortissue and tumor epithelium were analyzed. Vascularexpression in tumoral and extratumoral stroma, andintensity score, according to PSMA expression, in tumoralepithelium were analyzed.ResultsIn high grade gliomas, vascular PSMA staining percentageand vascular intensity score were significantlyhigher than low grade (p

AmaçGliomalar farklı dereceleri ile en sık karşılaşılan primerbeyin tümörleridir. Özellikle yüksek dereceli olanlardatümör anjiogenezi hem ana komponenetlerden biri,hem de prognoz açısından değerli bir belirleyicidir.Bu çalışmada, farklı hedef tedavileri belirleyebilmekiçin immunohistokimyasal metod ile glial tümörlerdeprostat spesifik membran antijeni (PSMA) salınımınıdeğerlendirmeyi amaçladık.Gereç ve YöntemDerece II (n=22), Derece III (n=19) ve Derece IV(n=52) glial tümörlü 93 hastadan alınan örneklerdePSMA antikorları immunohistokimyasal metod ile incelendi.Tümör dokusundaki PSMA boyanma yoğunluğuve tümör epitelleri incelendi. Tümör epitelindetümör ve tümör-dışı dokuda PSMA salınımına görevasküler salınım ve yoğunluk skoru analiz edildi.BulgularYüksek dereceli gliomalarda, vasküler PSMA boyanmayüzdesi ve vasküler yoğunluk skoru düşük derecelileregöre anlamlı olarak daha yüksek (p

glial tümör prostat-spesifik membran anjiogenez antigen

glial tumor prostate-spesific membrane angiogenesis antigen

Süleyman Demirel Üniversitesi Bilimsel Araştırma Projeleri Koordinasyon Birimi

TSG 2020-8134

Wernicke AG, Edgar MA, Lavi E, et al. Prostate Specific Membrane Antigen as a potential Novel Vascular Target for Treatment of Glioblastoma Multiforme. Aarchives of Pathology and Laboratory Medicine. 2011;135:1486–9.

Pasqualini R, Arap W, McDonald D. Probing the stractural and molecular diversity f tumor vasculature. Trends Molecular Medicine. 2002;8(12):563–71.

Plate K, Risau W. Angigenesis in malignant gliomas. Glia. 1995;15(3):339–47.

Scappaticci F. Mechanisms and future directions for angiogenesis based cancer therapies. Journal of Clinical Oncology. 2002;20(18):3906–27.

J.D. Mangadlao, X. Wang, C. McCleese, M. Escamilla, G. Ramamurthy, Z. Wang, M. Govande, J.P. Basilion, C. Burda, Prostate specific membrane antigen targeted gold nanoparticles for theranostics of prostate cancer, ACS Nano 12 (2018) 3714–3725.

Ni J, Miao T, Su M, KhanNU, Ju X, Chen H, Liu F, Han L. PSMA-targeted nonaparticles for spesific penetration of blood-brain tumor barrier and combined therapy of brain metastases. J of Controlled Release 2021;329:934-947.

Chang SS, Reuter VE, Heston WDW, et al. Five different Anti-Prostate- Specific Membrane Antigen (PSMA) antibodies confirm PSMA expression in tumor associated neovasculature. Cancer Research. 1999;59:3192.

Akhtar NH, Pail O, Saran A, et al. Prostate-Spaecific Membrane Antigen-Based Therapeutics. Advances in Urology. 2012 Article ID973820(doi:10.1155/2012/973820).

Grau SJ, Trillsch F, Luttichau Iv, et al. Lymphatic phenotype in tumor vessels in malignant gliomas. Neuropathology and Applied Neurobiology. 2008;34:675–9.

Saffar H, Noohi M, Tavangar SM, Saffar H, Azimi S. Expression of prostate-specific membrane antigen (PSMA) in brain glioma and its correlation with tumor grade. Iran J Pathol 2018;13(1):45-53.

Wernicke AG, Varma S, Greenwood EA et al Prostate‐specific membrane antigen expression in tumor‐associated vasculature of breast cancers. Apmis 2014;122(6):482-9.

Wernicke AG, Kim S, Liu H, Bander NH, Pirog EC Prostate-specific membrane antigen (PSMA) expression in the neovasculature of gynecologic malignancies: implications for PSMA-targeted therapy. Immunohistochemistry & Molecular Morphology 2017;25(4):271-6.

Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH (2007) Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 25:540–547.

Karyagar SS. PSMA- positive secondary tumors in ⁶⁸Ga PSMA PET/CT imaging in patients with prostate cancer. Eur Arch Med Res 2020;36(4):246-50.

Matsuda M, Ishikawa E, Yamamoto T, Hatano K, Joraku A, Lizumi Y, Masuda Y, Nishiyama H, Matsumara A. Potential use of prostate spesific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with ⁸⁹Zr-Df-IAB2M anti-PSMA minibody. J of Neuro-Oncology 2018;138:581-589.

Vargas J, Perez FG, Gomez E, Pitalua Q, Ornelas M, Ignacio E, et al. Histopathologic correlation with ⁶⁸Ga PSMA PET/CT in nonprostate tumors. Journal of Nuclear Medicine 2020;61 (Suppl 1):472.

Özülker F. Assessment of physiological distribution and normal variants of 68Ga PSMA-I&T PET/CT. Eur Arch Med Res 2018;34:235-42.

Demirci E, Sahin OE, Ocak M, Akovali B, Nematyazar J, Kabasakal L. Normal distribution pattern and physiological variants of 68GaPSMA-11 PET/CT imaging. Nucl Med Commun 2016;37:1169-79.

Holzgreve A, Biczok A, Ruf VC, Liesche-Starnecker F, Steiger K et al. PSMA expression in glioblastoma as a basis for theranostic approaches: a retrospective, correlation panel study including immunohistochemistry, clinical parameters and PET imaging. Front Oncol 2021;11:646387.